HALO MEXC RealStocks
Own real HALO shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-15 03:38:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Halozyme Therapeutics, Inc. (HALO) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $100.28, with a market capitalization of $11.48B and a P/E ratio of 23.64. Over the past 52 weeks, its price has ranged from $61.23 to $134.00. This page covers its latest market performance, valuation, price trends and company information.
$11.48B | |
$100.32 | |
$102.93 | |
$99.34 | |
$100.67 | |
1.94M | |
2.25M | |
23.64 | |
$134.00 | |
$61.23 | |
-- | |
-- |
Halozyme Therapeutics, Inc. (HALO) last closed at $100.28 as of 2026-11-14 00:57:00, down 0.37% ($0.37) from the previous close of $100.67.
During the latest regular trading session, HALO traded between $99.34 and $102.93, with a volume of 1.94M shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Halozyme Therapeutics, Inc. (HALO) moved from $122.96 to $100.28, representing a decline of 18.44% ($22.68).
The stock traded between $99.26 and $131.44 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.92 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 53.7%
HALO is currently trading at $100.28, placing it 53.7% of the way from its 52-week low of $61.23 to its 52-week high of $134.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 423 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Halozyme Therapeutics, Inc. (HALO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to HALO, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between HALO shares and USD.
HALO Shares to USD
1.00 HALO shares = 100.284 USD
Calculations are estimates based on the latest available price and are for reference only.